Weak U.S. Dollar Good for Biotechs!

December 1, 2006 · Filed Under General 

I ran across an article at thestreet.com written by Althea Chang. She makes a very important yet often forgotten point; biotechnology companies generally do well in a weakening U.S. dollar environment, at least those companies with international sales.

Analysts at Thomas Weisel Partners suggested that many of the larger biotechs, those with a relatively larger international revenue stream, will benefit the most. In fact, it is stated that 31% of all large biotechs’ sales are generated outside the U.S.! That is a significant number.

Large biotechs that should not be affected substantially by a weakening U.S. dollar include;

Amgen (AMGN) – 18% of sales from other nations
Biogen Idec (BIIB) – 40%
Genentech (DNA) – 16%
Genzyme (GENZ) – 45%
Gilead (GILD) – 53%

So why do big American biotechs have such large interest in international sales?

It has to do with the regulatory environment. It is well debated that the U.S. regulatory approval process is by far more strict than other countries, including European nations.

It is not unusual to see biotech companies get approval for their drug candidates in Europe well before the FDA clears them in the U.S., sometimes by a couple of years.



Leave a Reply

    Subscribe to BioHealth Investor BioHealth Investor RSS Feed